Compounds > 8-methyladenosine
Page last updated: 2024-12-08

8-methyladenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

8-methyladenosine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID171555
CHEBI ID178092
SCHEMBL ID967122
MeSH IDM0191561

Synonyms (14)

Synonym
CHEBI:178092
(2r,3r,4s,5r)-2-(6-amino-8-methylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
56973-12-7
8-methyl ado
2-(6-amino-8-methyl-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
8-methyl adenosine
(2r,3r,4s,5r)-2-(6-amino-8-methyl-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
8-methyladenosine
adenosine, 8-methyl-
RTGYRFMTJZYXPD-IOSLPCCCSA-N
SCHEMBL967122
DTXSID40205572
(2r,3r,4s,5r)-2-(6-amino-8-methyl-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
(2r,3r,4s,5r)-2-(6-amino-8-methyl-9h-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
purine nucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.66 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cytidine
[no description available]		2.0610cytidinesEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		3.2760adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
2'-5'-oligoadenylate trimer
2',5'-oligoadenylate: inhibits protein synthesis in cell-free systems		2.7130
agmatidine
agmatidine: structure in first source. agmatidine : Cytidine in which the 2-keto group on the cytosine ring is substituted by the amino group of agmatine.		2.0610cytidines
ConditionIndicatedRelationship StrengthStudiesTrials